PACS Group Q3 revenue beats on higher occupancy rates

By Reuters News


Overview

  • U.S. post-acute care provider's Q3 revenue rose 11.5%, beating analyst expectations

  • Adjusted EPS for Q3 increased 37% year-over-year

  • Company raised full-year 2026 revenue and adjusted EBITDA guidance


Outlook

  • PACS raises 2026 adj EBITDA outlook to $685 mln-$695 mln from $640 mln-$660 mln

  • Company lifts 2026 revenue forecast to $5.95 bln-$6.05 bln from $5.75 bln-$5.85 bln

  • Company says acquisition pipeline remains robust and it is actively evaluating new transactions


Result Drivers

  • OCCUPANCY AND SKILLED MIX - Co said higher occupancy rates and improved skilled mix contributed to revenue growth

  • EXPANSION - Co attributed growth to recent acquisitions in Florida and Texas

  • OPERATING EXECUTION - CFO said disciplined operating execution helped translate revenue growth into stronger profitability


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$1.50 bln

$1.46 bln (6 Analysts)

Q3 Net Income

$60.81 mln

Q3 Adjusted EBITDA

$175.70 mln

Q3 Operating Expenses

$1.40 bln

Q3 Operating Income

$99.72 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for PACS Group, Inc. is $60.00, about 31.6% above its November 2 closing price of $45.58

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 20 three months ago


Reuters Recommended Reads

  • Nov 2 - Diversified Healthcare Trust Q3 net loss narrows amid occupancy growth

  • Nov 2 - Sabra Health Care REIT Q3 revenue rises year-over-year

  • Nov 3 - AdaptHealth posts Q3 loss due to goodwill impairment charge


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.